Wound healing research often turns to peptides because they can guide tissue repair through targeted signals. Two of the most studied compounds in this space are GHK-Cu, a copper-binding tripeptide, and BPC-157, a synthetic pentadecapeptide. Both support repair, but they work in very different ways.
What Each Peptide Is
GHK-Cu stands for glycyl-L-histidyl-L-lysine bound to copper. It is a small three-amino-acid peptide that occurs naturally in human plasma. Researchers have studied it since the 1970s, mostly for its activity in skin and connective tissue.
BPC-157, also called Body Protection Compound-157, is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It was derived from a protective protein found in human gastric juice. Its other names include Pentadecapeptide, PL 14736, PL-10, and Bepecin.
So the two peptides differ in size, source, and the tissues they target. GHK-Cu is short and copper-bound. BPC-157 is longer and gut-derived. That structural gap helps explain why their healing profiles diverge.
How the Mechanisms Differ
GHK-Cu shuttles copper into cells, and copper is a cofactor for several enzymes involved in collagen and elastin formation. Studies in skin models suggest GHK-Cu also influences gene expression, with shifts in pathways tied to extracellular matrix remodeling and antioxidant defense.
BPC-157 acts through a broader signaling network. According to Sikiric and colleagues (2011), it upregulates growth factors such as VEGF and EGF and promotes new blood vessel formation. This pro-angiogenic activity drives much of the repair seen in animal models.
In short, GHK-Cu leans toward matrix and skin chemistry. BPC-157 leans toward vascular signaling and systemic tissue protection. The two peptides hit different levers in the same broad process.
Tissue Strengths and Research Focus
GHK-Cu research clusters around skin and surface wounds. Animal and cell studies report effects on collagen synthesis, hair follicle activity, and certain markers of wound closure. It has also drawn attention in dermatology research as a small peptide that can influence many genes at once.
BPC-157 research spans a wider tissue list. It has been examined in models of gastric ulcers, intestinal injury, tendon damage, and nerve repair. In one example, Chang and colleagues (2011) reported that BPC-157 sped healing of cut Achilles tendons in rats by encouraging fibroblast outgrowth and VEGF expression.
Researchers comparing the two often note that GHK-Cu fits surface and dermal questions, while BPC-157 fits deeper musculoskeletal and gastrointestinal questions. Some studies use them in parallel rather than head-to-head.
Open Questions for Investigators
Both peptides have produced encouraging preclinical data, yet large controlled human trials are limited. For GHK-Cu, scientists still debate how copper delivery, dose, and formulation shape outcomes outside the skin. For BPC-157, much of the published literature comes from a single research group, and replication in independent labs is still an ongoing process.
Stability, route of delivery, and species differences also complicate direct comparisons. A peptide that performs well in a rodent tendon study may behave differently in a different model or tissue.
Researchers continue to map how GHK-Cu and BPC-157 fit into the broader picture of tissue repair, and clear human evidence is still being gathered. These compounds are intended for research use only and are not for human consumption.